HopeStage
Back to overview

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Topics
More filters
27277studies shown
Showing 6,229-6,240 of 27,277
Drug study icon
CompletedNCT01177943

A Bioequivalence (BE) Study in Healthy Subjects

Official study title

LY139603 Bioequivalence Study Comparing Atomoxetine Oral Solution and Capsule Formulation in Healthy Adult Male Japanese Subjects

This study has finished and is no longer accepting participants.

In Fukuoka
ADHDMedication studyAges 20–55
Countries
Japan
Sponsor
Eli Lilly and Company
Drug study icon
CompletedNCT00892489

A Bioequivalence Study of 15 mg ER OROS Paliperidone

Official study title

Pivotal Bioequivalence Study With 15 mg ER OROS Paliperidone Comparing the Phase 3 Formulation With the To-be-marketed Formulation and Evaluation of Food Effect on the to be Marketed Formulation in Healthy Male Subjects

This study has finished and is no longer accepting participants.

Location not clearly listed
SchizophreniaMedication studyAges 18–55
Countries
Sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Drug study icon
CompletedNCT05024747

21 Milligram (mg) Nicotine Transdermal Patches (NicoDerm CQ, GlaxoSmithKline [GSK] Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) for Addiction

Official study title

A Randomized, Open Label, Single Center, Single Dose, Two Period, Two Sequence Crossover Bioequivalence Study of 21 mg Nicotine Transdermal Patches (NicoDerm CQ, GSK Dungarvan) Compared to the Current Marketed 21 mg Nicotine Transdermal Patches (NicoDerm CQ, Alza) in Healthy Adult Smokers

This study has finished and is no longer accepting participants.

In Springfield
AddictionMedication studyAges 21–55
Countries
United States
Sponsor
HALEON
Other study type icon
CompletedNCT02688374

Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) for Addiction

Official study title

A Single-Dose, Open-Label, Three-way Crossover Bioequivalence Study of Three, 2 mg Nicotine Chewing Gums (Two Tests and One Reference) in Chinese Male Healthy Adult Smokers

This study has finished and is no longer accepting participants.

In Beijing
AddictionInterventional studyAges 18–45
Countries
China
Sponsor
GlaxoSmithKline
Other study type icon
UnknownNCT06515522

A Biological Signature for the Early Differential Diagnosis of Psychosis

Official study title

A Biological Signature for the Early Differential Diagnosis of Psychosis: Unveiling the Differences Between Mood Disorders and Schizophrenia With Multimodal Machine Learning Techniques

Current recruitment status is unconfirmed.

Location not clearly listed
Schizophrenia, Depression, ...Observational studyAges 18–65
Countries
Sponsor
IRCCS San Raffaele
Drug study icon
CompletedNCT05113771

Liafensine for Depression

What is this study about?

This study evaluated the safety and effectiveness of Liafensine for people with depression.

This study has finished and is no longer accepting participants.

Multiple locations, including Huntsville
DepressionMedication studyAges 18–70
Countries
United States, Canada
Sponsor
Denovo Biopharma LLC
Behavioral study icon
CompletedNCT05464121

A Blended Intervention for Adjustment Disorder.

Official study title

A Blended Intervention for Adjustment Disorder: Feasibility Trial and Preliminary Effectiveness.

This study has finished and is no longer accepting participants.

In Castellon
Adjustment disorderBehavioural studyAges 18+
Countries
Spain
Sponsor
Universitat Jaume I
Drug study icon
CompletedEUCTR 2007-004482-18

A blinded-initiation study of medication satisfaction in subjects with schizophrenia treated with paliperidone ER after suboptimal response to oral risperidone.

This study has finished and is no longer accepting participants.

Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.

In Czech Republic
SchizophreniaHistorical research record
Countries
Czechia, Slovakia
Sponsor
Ortho-McNeil Janssen Scientific Affairs, LLC
Drug study icon
TerminatedNCT07329621

Binding of MSP-2020 to Serotonin 5-HT2A Receptors for Depression

Official study title

A Phase 1, Open-label, Positron Emission Tomography (PET) Trial to Measure Serotonin 5-HT2A Receptor Occupancy Following Single Oral Doses of MSP-2020 in Healthy Male Adults

This study ended early.

In London
DepressionMedication studyAges 23–55
Countries
United Kingdom
Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc. (Pharmaceutical company)

Registry coverage

We gather information about mental health clinical trials from the public registries we index. Coverage is still expanding, so some studies may not appear yet.